How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

27,537 results for

Topical Corticosteroid

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

161. Assessment of adherence to topical corticosteroids in bullous pemphigoid patients. (PubMed)

Assessment of adherence to topical corticosteroids in bullous pemphigoid patients. 26556709 2017 03 06 2017 08 17 1365-2133 174 4 2016 Apr The British journal of dermatology Br. J. Dermatol. Assessment of adherence to topical corticosteroids in patients with bullous pemphigoid. 919-21 10.1111/bjd.14285 Sobocinski V V Department of Dermatology, INSERM U 905, Institute for Research and Innovation in Biomedicine, Rouen University Hospital, University of Rouen, Rouen, France. valerie.sobocinski

2015 British Journal of Dermatology

162. Patient-reported outcomes after discontinuation of long-term topical corticosteroid treatment for atopic dermatitis: a targeted cross-sectional survey (PubMed)

Patient-reported outcomes after discontinuation of long-term topical corticosteroid treatment for atopic dermatitis: a targeted cross-sectional survey Topical corticosteroid (TCS) treatment is widely prescribed for atopic dermatitis (AD). However, TCS treatment is associated with tachyphylaxis, and discontinuation after long-term use may cause exacerbation of symptoms. Some AD patients are reluctant to use TCS.To evaluate patient-reported short- and long-term outcomes after discontinuation

Full Text available with Trip Pro

2015 Drug, healthcare and patient safety

163. Long-Term Outcome of Treatment with Topical Corticosteroids for Severe Dry Eye Associated with Sjögren's Syndrome (PubMed)

Long-Term Outcome of Treatment with Topical Corticosteroids for Severe Dry Eye Associated with Sjögren's Syndrome This retrospective study was performed to analyze the long-term outcome of topical corticosteroid treatment for severe dry eye associated with Sjögren's syndrome (SS). Patients who had severe dry eye associated with SS were topically treated with loteprednol etabonate 0.5% (group A, n=66) or fluorometholone 0.1% (group B, n=67) twice daily and were followed up for 2 years. Visual (...) . No significant differences between the groups were found in any parameter during follow-up. At 24 months, the number of patients with IOP elevation of more than 2 mmHg compared with baseline was 4 in group A (6.1%) and 9 in group B (13.4%). The mean IOP in these patients was lower in group A than in group B (15.00±0.82 mmHg versus 16.50±1.12 mmHg; p=0.04). Long-term application of low-dose topical corticosteroids is effective for controlling signs and symptoms of chronic, severe dry eye associated with SS

Full Text available with Trip Pro

2015 Chonnam medical journal

164. Vulvovaginal photodynamic therapy versus topical corticosteroids in genital erosive lichen planus: a randomized controlled trial. (PubMed)

Vulvovaginal photodynamic therapy versus topical corticosteroids in genital erosive lichen planus: a randomized controlled trial. Genital erosive lichen planus (GELP) in women is a chronic inflammatory disease characterized by painful vulval and vaginal erosions. Topical photodynamic therapy (PDT) is increasingly used in premalignant and malignant diseases and may have an effect in inflammatory diseases.To assess the feasibility, efficacy and safety of hexyl 5-aminolevulinate-hydrocloride (...) (HAL)-PDT in GELP.Forty women, diagnosed with GELP at a specialized vulva clinic, were randomized to one session HAL-PDT in vulva and/or vagina (n = 20) or daily applications of clobetasol propionate 0·05% ointment in vulva and optional hydrocortisone acetate 1·0% foam in vagina for 6 weeks (n = 20). After 6 weeks, all patients were allowed to use topical corticosteroids as needed. Clinical examinations were performed at weeks 0, 6 and 24, using a clinical score developed for the study. All

Full Text available with Trip Pro

2015 The British journal of dermatology

165. Topical combination therapy with vitamin D3 and corticosteroid ointment for palmoplantar pustulosis: A prospective, randomized, left-right comparison study. (PubMed)

Topical combination therapy with vitamin D3 and corticosteroid ointment for palmoplantar pustulosis: A prospective, randomized, left-right comparison study. Vitamin D3 ointment and corticosteroid ointment are both used for the treatment of palmoplantar pustulosis (PPP). However, to date there is no systematic study of the efficacy of combination therapy for the treatment of PPP.We compared the efficacy of a topical combination therapy with vitamin D3 and a topical corticosteroid (...) with that of topical corticosteroid alone in the treatment of PPP.We evaluated left-right comparison study of the efficacy of a combination therapy consisting of maxacalcitol ointment and betamethasone butyrate propionate ointment (BBP), and monotherapy with BBP alone in 27 patients with PPP for 8 weeks.The improvement in the symptom (erythema, pustules/vesicles, hyperkeratosis/scales) scores was high for the combination therapy. In particular, the improvement rate for pustules/vesicles at week 8 after

2015 The Journal of dermatological treatment

166. Cushing's Syndrome in a 6-month-old Boy: A Rare Side-effect due to Inadequate use of Topical Corticosteroids. (PubMed)

Cushing's Syndrome in a 6-month-old Boy: A Rare Side-effect due to Inadequate use of Topical Corticosteroids. 26038976 2016 10 17 2016 12 30 1651-2057 96 1 2016 Jan Acta dermato-venereologica Acta Derm. Venereol. Cushing's Syndrome in a 6-month-old Boy: A Rare Side-effect due to Inadequate use of Topical Corticosteroids. 138-9 10.2340/00015555-2151 Ciccone Sara S Unit of Pediatric Endocrinology and Diabetes, S. Anna Hospital of Ferrara, IT-44124 Ferrara, Italy. sara.ciccone@unife.it. Marini

Full Text available with Trip Pro

2015 Acta Dermato-Venereologica

167. Evaluation of Fluid Retention Due to Superpotent Topical Corticosteroid

Evaluation of Fluid Retention Due to Superpotent Topical Corticosteroid Evaluation of Fluid Retention Due to Superpotent Topical Corticosteroid - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Evaluation (...) of Fluid Retention Due to Superpotent Topical Corticosteroid (RECOPB) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT02360202 Recruitment Status : Recruiting First Posted : February 10, 2015 Last Update Posted : August 30

2015 Clinical Trials

168. Impact of saline irrigation and topical corticosteroids on the postsurgical sinonasal microbiota. (PubMed)

Impact of saline irrigation and topical corticosteroids on the postsurgical sinonasal microbiota. Topical treatments with nasal saline irrigation, topical steroid sprays, or corticosteroid rinses can improve sinonasal symptoms in chronic rhinosinusitis (CRS). However, the impact of these therapies on commensals (Corynebacterium) and on biofilm pathogens associated with CRS (Staphylococcus aureus and Pseudomonas) is not well characterized.Paired nasal and sinus swabs were collected (...) endoscopically from 28 controls and 14 CRS patients with nasal polyposis (CRSwNP) who had not received systemic antibiotics or corticosteroids in the previous 8 weeks. Total DNA from swab eluents were extracted and analyzed by 16S rRNA gene-based pyrosequencing. A total of 359,077 reads were obtained and classified taxonomically. The association of use of topical therapies with sinonasal microbiota composition was assessed by factor/vector-fitting. The proportional abundances of sinonasal bacteria between

Full Text available with Trip Pro

2015 International forum of allergy & rhinology

169. Pharmacists' knowledge about use of topical corticosteroids in atopic dermatitis: Pre and post continuing professional development education. (PubMed)

Pharmacists' knowledge about use of topical corticosteroids in atopic dermatitis: Pre and post continuing professional development education. Topical corticosteroids (TCS) are the standard of care in paediatric atopic dermatitis (pAD). Parents commonly cite TCS phobia as a major impediment to treatment adherence. Misinformation on TCS side-effects can impact on perceptions of TCS safety. We aimed to assess pharmacists' beliefs and information on the safety of TCS in pAD treatment and determine

2015 Australasian Journal of Dermatology

170. Silver Nitrate Application and Topical Corticosteroids for Hypergranulation Tissue

Silver Nitrate Application and Topical Corticosteroids for Hypergranulation Tissue Silver Nitrate Application and Topical Corticosteroids for Hypergranulation Tissue - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before (...) adding more. Silver Nitrate Application and Topical Corticosteroids for Hypergranulation Tissue The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02398539 Recruitment Status : Unknown Verified May 2015 by Eloise Lemon, Akron Children's Hospital. Recruitment status was: Recruiting First Posted : March 25

2015 Clinical Trials

171. Topical intranasal corticosteroids and growth velocity in children: a meta-analysis. (PubMed)

Topical intranasal corticosteroids and growth velocity in children: a meta-analysis. There is no consensus regarding the effects on growth velocity of intranasal topical corticosteroid (ITC) use in children. The objective of this study was to determine whether ITC use reduces growth velocity in children with allergic rhinitis (AR).A literature search of the National Center for Biotechnology Information PubMed, EMBASE, SCOPUS, and Cochrane databases from January 1, 1988 to October 7, 2013

2015 International forum of allergy & rhinology

172. A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of alitretinoin (BAL4079) in the treatment of severe chronic hand eczema refractory to potent topical corticosteroid therapy. (PubMed)

A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of alitretinoin (BAL4079) in the treatment of severe chronic hand eczema refractory to potent topical corticosteroid therapy. Severe chronic hand eczema (sCHE) is a persistent, disfiguring disease that responds poorly to conventional treatment and causes substantial physical and psychological disability. The objective of this study was to evaluate efficacy and safety of oral alitretinoin in sCHE (...) in a Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study comparing alitretinoin with placebo. Efficacy was assessed every 4 weeks during treatment and 4 weeks after end of treatment (EOT, 24 weeks); responders were assessed every 4 weeks for a further 48 weeks after EOT. The study was conducted at academic and private dermatology centers. The participants were 596 patients with sCHE refractory to potent topical corticosteroids. Patients were treated with daily oral

2015 Journal of drugs in dermatology : JDD

173. Cutaneous Rosai-Dorfman Disease Located on the Breast: Rapid Effectiveness of Methotrexate After Failure of Topical Corticosteroids, Acitretin and Thalidomide. (PubMed)

Cutaneous Rosai-Dorfman Disease Located on the Breast: Rapid Effectiveness of Methotrexate After Failure of Topical Corticosteroids, Acitretin and Thalidomide. 25632986 2016 03 23 2015 06 24 1651-2057 95 6 2015 Jul Acta dermato-venereologica Acta Derm. Venereol. Cutaneous Rosai-Dorfman Disease Located on the Breast: Rapid Effectiveness of Methotrexate After Failure of Topical Corticosteroids, Acitretin and Thalidomide. 758-9 10.2340/00015555-2057 Nadal Marion M Department of Dermatology, CHRU

Full Text available with Trip Pro

2015 Acta Dermato-Venereologica

174. Adverse effects of topical corticosteroids in paediatric eczema: Australasian consensus statement. (PubMed)

Adverse effects of topical corticosteroids in paediatric eczema: Australasian consensus statement. Atopic eczema is a chronic inflammatory disease affecting about 30% of Australian and New Zealand children. Severe eczema costs over AUD 6000/year per child in direct medical, hospital and treatment costs as well as time off work for caregivers and untold distress for the family unit. In addition, it has a negative impact on a child's sleep, education, development and self-esteem. The treatment (...) of atopic eczema is complex and multifaceted but a core component of therapy is to manage the inflammation with topical corticosteroids (TCS). Despite this, TCS are often underutilised by many parents due to corticosteroid phobia and unfounded concerns about their adverse effects. This has led to extended and unnecessary exacerbations of eczema for children. Contrary to popular perceptions, (TCS) use in paediatric eczema does not cause atrophy, hypopigmentation, hypertrichosis, osteoporosis, purpura

Full Text available with Trip Pro

2015 Australasian Journal of Dermatology

175. Ocular side-effects of topical corticosteroids: what a dermatologist needs to know. (PubMed)

Ocular side-effects of topical corticosteroids: what a dermatologist needs to know. Topical corticosteroids are used frequently in dermatology and atopic dermatitis without significant adverse effects. Though ocular diseases such as glaucoma and cataracts are known complications of systemic corticosteroids, the role of topical corticosteroids is limited to case reports. This review assesses the literature regarding topical steroids and their role in ocular diseases. There is evidence of harm (...) to vision when potent topical corticosteroids are inappropriately used for prolonged periods to periorbital sites. There is no evidence to date that weak TCS to the face or potent TCS to areas other than the eyes results in ocular complications. Further research trials are required in this area. © 2015 The Australasian College of Dermatologists.

2015 Australasian Journal of Dermatology

176. Topical Tacrolimus is equally effective in treating patients with Oral Lichen Planus (OLP) as compared to Topical clobetasol

into 2 groups: twenty patients were assigned the use of clobetasol propionate (0.05%) ointment (topical corticosteroid) twenty patients were assigned the use of tacrolimus (0.1%) ointment (topical immunosuppressant), for eight weeks each. The patients were instructed to apply the ointment twice a day during the treatment period. Both groups were additionally instructed to use chlorhexidine mouthwash three times per day during the 8 week period. All patients were assessed at 2 weeks, 4 weeks and 8 (...) Topical Tacrolimus is equally effective in treating patients with Oral Lichen Planus (OLP) as compared to Topical clobetasol UTCAT2490, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title Topical Tacrolimus is Equally Effective in Treating Patients with Oral Lichen Planus (OLP) as Compared to Topical Clobetasol Clinical Question Can topical tacrolimus be used as an alternate to topical clobetasol for treatment of OLP

2013 UTHSCSA Dental School CAT Library

177. Efficacy of Viscosupplementation Associated With Intra-articular Corticosteroid Injection Versus Intra-articular Injection of Corticosteroids Alone in Osteoarthritis of Hip

: November 2015 Actual Study Completion Date : November 2015 Resource links provided by the National Library of Medicine related topics: related topics: Arms and Interventions Go to Arm Intervention/treatment Experimental: injection of viscosupplementation and corticosteroid experimental group Device: Experimental group patient receive intra articular injection (hip joint) of viscosupplementation in combination with corticosteroid Active Comparator: injection of corticosteroid control group Device (...) Efficacy of Viscosupplementation Associated With Intra-articular Corticosteroid Injection Versus Intra-articular Injection of Corticosteroids Alone in Osteoarthritis of Hip Efficacy of Viscosupplementation Associated With Intra-articular Corticosteroid Injection Versus Intra-articular Injection of Corticosteroids Alone in Osteoarthritis of Hip - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information

2016 Clinical Trials

178. Combination Corticosteroids+5-aminosalicylic Acids Compared to Corticosteroids Alone (for Ulcerative Colitis).

moderate UC. Thus, in most cases, when a patient with UC experiences a flare while taking 5-ASA therapy, treatment is usually optimized by maximizing the oral dose to 4gr/day and adding topical therapy until the flare is controlled. If this is unhelpful, or if the flare is severe to begin with, corticosteroids are usually prescribed. However, there are very scarce data comparing steroids versus 5-ASA in the treatment of severe UC exacerbation. In 1962 truelove et al compared topical and systemic (...) if the addition of 5-ASA (Oral and/or topical) to corticosteroids will confer additional benefit and improve patients outcomes. Thus, in practical terms, the decision whether to stop or continue 5-ASA treatment or whether to add 5-ASA to steroids in the treatment of moderate-severe UC exacerbation is taken on an arbitrary basis. This is important shortcoming and knowledge gap in current medicine, as patients admitted with moderate-severe UC flare who do not respond to corticosteroids and require salvage

2016 Clinical Trials

179. Ibrutinib in Combination With Corticosteroids vs Placebo in Combination With Corticosteroids in Subjects With New Onset cGVHD

in Combination With Corticosteroids in Subjects With New Onset Chronic Graft Versus Host Disease (cGVHD) (INTEGRATE) Study Start Date : December 2016 Estimated Primary Completion Date : March 2020 Estimated Study Completion Date : March 2020 Resource links provided by the National Library of Medicine related topics: available for: resources: Arms and Interventions Go to Arm Intervention/treatment Experimental: Ibrutinib Ibrutinib in combination with prednisone Drug: ibrutinib Ibrutinib capsules administered (...) Ibrutinib in Combination With Corticosteroids vs Placebo in Combination With Corticosteroids in Subjects With New Onset cGVHD Ibrutinib in Combination With Corticosteroids vs Placebo in Combination With Corticosteroids in Subjects With New Onset cGVHD - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached

2016 Clinical Trials

180. Late reported clinical trial of the week: Cyclosporine or corticosteroids as an adjunct to plasma exchange in thrombotic thrombocytopenic purpura (NCT00713193)

Late reported clinical trial of the week: Cyclosporine or corticosteroids as an adjunct to plasma exchange in thrombotic thrombocytopenic purpura (NCT00713193) Late reported clinical trial of the week: Cyclosporine or corticosteroids as an adjunct to plasma exchange in thrombotic thrombocytopenic purpura (NCT00713193) - The BMJ ---> Nick DeVito and Ben Goldacre Today we describe a trial that reported late, in breach of the FDA Amendments Act 2007. This late reporting is especially notable (...) ) guidelines are broader: they require all trials of medicinal products registered on their (EUCTR) since 2004 to report results within one year of completion. Our and show all individual trials that breach these legal requirements. Each week we write about one unreported clinical trial: you can read more background , and past entries are . Trials NCT00713193 This week’s late reported trial is titled “A multi-center, randomized study of cyclosporine or corticosteroids as an adjunct to plasma exchange

2018 The BMJ Blog

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>